ARTICLE | Company News

Cellectis genomics news

December 7, 2009 8:00 AM UTC

Cellectis said the European Patent Office (EPO) upheld the company's European Patent EP 1,485,475 related to engineering methods for meganucleases, but reduced the scope of the patent's claims. Claims to hybrid meganucleases were restricted to cover only certain meganucleases. Cellectis said no products would be impacted by the reduced scope, but it is considering an appeal. ...